Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology: Clinical practice guideline for social anxiety disorder (2021)

Author:

Asakura Satoshi123,Yoshinaga Naoki14ORCID,Yamada Hisashi125ORCID,Fujii Yutaka123ORCID,Mitsui Nobuyuki123ORCID,Kanai Yoshihiro16ORCID,Inoue Takeshi127ORCID,Shimizu Eiji128ORCID

Affiliation:

1. Japanese Society of Anxiety and Related Disorders Tokyo Japan

2. Japanese Society of Neuropsychopharmacology Tokyo Japan

3. Department of Psychiatry, Hokkaido University Graduate School of Medicine/Health Care Center Hokkaido University Sapporo Japan

4. School of Nursing, Faculty of Medicine University of Miyazaki Miyazaki Japan

5. Department of Neuropsychiatry Hyogo College of Medicine Nishinomiya Japan

6. Department of Psychology and Behavioral Sciences, Faculty of Human Sciences Tohoku Gakuin University Sendai Japan

7. Department of Psychiatry Tokyo Medical University Tokyo Japan

8. Department of Cognitive Behavioral Physiology, Graduate School of Medicine Chiba University Chiba Japan

Abstract

AbstractThe development of clinical practice guidelines for social anxiety disorder began in March 2018 when the Joint Clinical Practice Guideline Development Committee for Anxiety and Obsessive–Compulsive Disorders was formed by the Japanese Society of Anxiety and Related Disorders and Japanese Society of Neuropsychopharmacology to jointly develop guidelines for anxiety and obsessive–compulsive disorders. Based on the universal concept of evidence‐based medicine, three clinical questions (CQs) about pharmacotherapy and psychotherapy were developed for clinical guidelines for social anxiety disorder, panic disorders, and obsessive–compulsive disorder in accordance with the Minds Manual for Guidelines Development 2017 by the Japan Council for Quality Health Care: CQ1—“What is the recommended pharmacotherapy for social anxiety disorder in adults?”; CQ2—“What is the recommended psychotherapy (psychological intervention) for social anxiety disorder in adults?”; and CQ3—“What are the recommendations regarding monotherapy and combination therapy for social anxiety disorder in adults in terms of pharmacotherapy and psychotherapy (psychological interventions)?” Summarized recommendations for social anxiety disorder in adults are selective serotonin reuptake inhibitors and serotonin‐norepinephrine reuptake inhibitor for CQ1, cognitive behavioral therapy for CQ2, and there are no recommendations regarding monotherapy and combination therapy for CQ3. These were answered by considering the balance between benefits and harms based on systematic reviews of each. The aim of this brief guideline for the standard‐of‐care (i.e., medical treatment) for social anxiety disorder in adults (18 years and older) was to help “shared decision making,” in which medical professionals, including physicians, and patients share scientific evidence to decide on a course of treatment.

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Pharmacology,Clinical Psychology

Reference18 articles.

1. Pharmacotherapy for social anxiety disorder (SAnD);Williams T;Cochrane Database Syst Rev,2017

2. The diagnosis of and treatment recommendations for anxiety disorders;Bandelow B;Dtsch Arztebl Int,2014

3. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3